Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03792763
Other study ID # AGMT_MM-3
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 30, 2019
Est. completion date September 14, 2024

Study information

Verified date November 2023
Source Arbeitsgemeinschaft medikamentoese Tumortherapie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, 2-arm phase II, placebo-controlled, multi-center study, where the investigators aim to evaluate whether the reported benefits of denosumab, delay of SRE and decrease in myeloma growth promotion, reduce the risk of progression of high-risk SMM and of early 'SLiM CRAB' myeloma into active, symptomatic CRAB positive myeloma or serological progression. In addition, tolerability of long-term treatment will be assessed.


Description:

The aim of this study is to evaluate whether the transition of early Multiple Myeloma (High Risk Smouldering Multiple Myeloma SMM or "Ultra High Risk" SMM) or SLiM CRAB positive multiple myeloma to a symptomatic multiple myeloma (MM) can be reduced or delayed by the administration of denosumab. With the exception of clinical studies, there are currently no standardized treatment options for SMM. Ultra-high risk SMM is already part of early active myeloma and is therefore in some cases treated according to a standard myeloma protocol (Revlimid-Dexamethasone, Velcade melphalan prednisone, melphalan prednisone thalidomide, or others). However, most practitioners recommend a wait-and-see strategy, since depending on the initial situation within two years only 58-95% of patients develop an 'active' MM and 5-42% of the patients had a stable disease and therefore do not necessarily have to be treated immediately. Denosumab is a human monoclonal antibody (IgG2) which binds to RANKL with high affinity and specificity. RANKL (receptor activator of NF-κB Ligand) is a protein that is responsible for the formation, function and survival of osteoclasts (cell type responsible for bone resorption) Increased osteoclast activity, stimulated by RANKL, is a key mediator of the bone resorption in bone metastases and MM. Thus the activity of denosumab is resulting in a reduced number and function of osteoclasts and thus decreases the bone resorption and tumor-induced bone destruction. After an initial phase of about 14 days (screening), the patients will be randomized 1:1 in one of the two study groups (arm A: denosumab or arm B: placebo). The study is double-blinded. The planned duration of therapy is 3 years. Patients receive denosumab or placebo every 4 weeks for 6 months, then every 3 months until a total of 3 years or progression. After completion of the therapy, an observation and follow-up phase is carried out with patient visits every 3 months until the end of the treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 8
Est. completion date September 14, 2024
Est. primary completion date September 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Able to provide written informed consent in accordance with federal, local, and institutional guidelines - Must meet criteria of high-risk smoldering MM or early "SLiM CRAB" MM based on the criteria described below: - High-risk SMM is defined here according to the revised Mayo Clinical criteria (2 out of 3 criteria must be fulfilled): - Bone marrow clonal plasma cells > 20% - Serum M protein > 2.0g/dL - Serum-free light chain ratio > 20, measured with "Binding site Kit" - Early 'SLiM CRAB' multiple myeloma - Patients must present with only one of the following features - Bone marrow clonal plasma cells = 60%, or - Serum FLC ratio = 100 (kappa-LC leading) or = 0.01 (lambda-LC leading), measured with "Binding site Kit", or - >1 Focal bone lesion of =5mm (not associated with osteolysis, detected by PET-CT or whole-body low-dose CT (WBLDCT)) - Time from diagnosis of high-risk SMM or SLIM CRAB positive, early MM to study enrollment: <5 years Exclusion Criteria: - ECOG >3 - Active, symptomatic MM (fulfilling CRAB-criteria) - Non-secretory MM, extramedullary plasmacytoma, plasma cell leukemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) - MGUS - Hypocalcemia (can be corrected by drug intervention before start of treatment) - Second malignancy within the past 5 years except: - Adequately treated basal cell or squamous cell skin cancer - Carcinoma in situ of the cervix - Prostate cancer Gleason score = 6 with stable prostate-specific antigen (PSA over 12 months) - Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins) - Treated medullary or papillary thyroid cancer - Similar condition with an expectation of > 95% five-year disease-free survival - Active infection within the 14 days prior to randomization requiring systemic antibiotics and/or antiviral therapy - Patients with known active or latent tuberculosis - Known human immunodeficiency virus (HIV) seropositivity or active hepatitis C or hepatitis B infection (subjects with past hepatitis B virus [HBV] infection or resolved HBV infection defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test are eligible; subjects positive for hepatitis C virus [HCV] antibody are eligible only if polymerase chain reaction [PCR] is negative for HCV RNA.) - Participation in another interventional study within the 28 days prior to randomization - Any other clinically significant medical disease or social condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent, be compliant with study procedures, or provide accurate information. - Prior administration of denosumab - Prior exposure to any experimental or approved anti-myeloma agent - Use of oral bisphosphonates with a cumulative exposure of more than 1 year (washout period for allowed bisphosphonate exposure 1 month) - More than 1 previous dose of IV bisphosphonate or teriparatide administration (washout period for allowed bisphosphonate exposure 1 month) - Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw - Active dental or jaw condition which requires oral surgery, including tooth extraction - Subject is pregnant or breastfeeding, or planning to become pregnant within 7 months after the end of treatment - Female subject of childbearing potential is not willing to use, in combination with her partner, a highly effective and in addition an effective method of contraception during treatment and for 5 months after the end of treatment - Known sensitivity to denosumab (including all components of the formulation) or any of the products to be administered during the study (eg, mammalian derived products, calcium, or vitamin D) - Subject is receiving or is less than 30 days since ending other experimental devices or drugs (no marketing authorization for any indication). - Subject will not be available for follow-up assessment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
Placebo 1.7 ml Subcutaneous Solution
Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM

Locations

Country Name City State
Austria Medizinische Universitaet Graz, Univ.-Klinik f. Innere Medizin, Onkologie Graz
Austria Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V Hämatologie und Onkologie Innsbruck
Austria LKH Hochsteiermark, Standort Leoben, Abteilung für Innere Medizin und Hämatologie und internistische Onkologie Leoben
Austria BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie Linz
Austria Kepler Universitaetsklinikum Klinik f. Interne 3, Med Campus III Linz
Austria IIIrd Medical Department, Private Medical University Hospital Salzburg Salzburg
Austria Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung Wien
Austria Krankenhaus St. Vinzenz Zams, Innere Medizin, Internistische Onkologie und Hämatologie Zams
Germany University Hospital Würzburg, Department of Internal Medicine 2 Würzburg
Israel Tel Aviv Sourasky Medical Center, Department of Hematology, Tel Aviv

Sponsors (3)

Lead Sponsor Collaborator
Arbeitsgemeinschaft medikamentoese Tumortherapie Amgen, Assign Data Management and Biostatistics GmbH

Countries where clinical trial is conducted

Austria,  Germany,  Israel, 

References & Publications (2)

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4. — View Citation

Mateos MV, Landgren O. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treat Res. 2016;169:3-12. doi: 10.1007/978-3-319-40320-5_1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to progression Time from randomization to transformation to symptomatic, active MM (defined as progression to active multiple myeloma according to IMWG diagnosis criteria 2014) or progression of disease according to IMWG response criteria 2016 78 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months for a maximum of 36 months)
Secondary Percentage of patients transforming in 3 years Percentage of patients with high-risk SMM and early 'slim CRAB' positive MM transforming to CRAB positive multiple myeloma and/or developing serological progression (as defined by IMWG criteria 2016 for MM) within 3 years 36 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months)
Secondary Overall survival To determine the overall survival of patients receiving either denosumab or placebo 78 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months for a maximum of 36 months)
Secondary Time to first skeletal-related event To determine the time to first skeletal-related event for patients receiving either denosumab or placebo. • Imaging: low dose wbCT (details will be described in a separate guidance document) or PET-CT mandatory 78 months (baseline and every 6 months thereafter until progression or maximum of 3 years).
Secondary Incidence of bone lesions as MM defining events To determine the incidence of bone lesions as MM defining events. • Imaging: low dose wbCT (details will be described in a separate guidance document) or PET-CT mandatory. 78 months (baseline and every 6 months thereafter until progression or maximum of 3 years).
Secondary Time to first anti-myeloma treatment To determine the time to first anti-myeloma treatment for patients receiving either denosumab or placebo 78 months (the first 6 cycles are 28 days, thereafter each cycle is 3 months for a maximum of 36 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1
Recruiting NCT04111809 - Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care

External Links